Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Page 1
Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronism.
Izzo JL Jr, Hong M, Hussain T, Osmond PJ. Izzo JL Jr, et al. J Clin Hypertens (Greenwich). 2019 Aug;21(8):1183-1190. doi: 10.1111/jch.13597. Epub 2019 Jul 26. J Clin Hypertens (Greenwich). 2019. PMID: 31347775 Free PMC article.
Whether aldosterone itself contributes directly to macro- or microcirculatory disease in man or to adverse cardiovascular outcomes is not fully known. We report our long-term single-practice experience in an unusual group of five patients with chronic hyperaldosteronism (H …
Whether aldosterone itself contributes directly to macro- or microcirculatory disease in man or to adverse cardiovascular outcomes is not fu …
Long-term BP control and vascular health in patients with hyperaldosteronism treated with low-dose, amiloride-based therapy.
Izzo JL Jr, Hong M, Hussain T, Osmond PJ. Izzo JL Jr, et al. J Clin Hypertens (Greenwich). 2019 Jul;21(7):922-928. doi: 10.1111/jch.13567. Epub 2019 Jun 6. J Clin Hypertens (Greenwich). 2019. PMID: 31169971 Free PMC article.
Whether aldosterone itself contributes directly to macro- or microcirculatory disease in man or to adverse cardiovascular outcomes is not fully known. We report our long-term single-practice experience in 5 patients with chronic hyperaldosteronism (HA, including 3 with glu …
Whether aldosterone itself contributes directly to macro- or microcirculatory disease in man or to adverse cardiovascular outcomes is not fu …
Renal denervation for human hypertension: is there a future?
Izzo JL Jr, Tobe SW. Izzo JL Jr, et al. J Am Soc Hypertens. 2016 May;10(5):390-2. doi: 10.1016/j.jash.2016.02.016. Epub 2016 Mar 8. J Am Soc Hypertens. 2016. PMID: 27049792
In man, catheter ablation of renal nerves has been undertaken in the late phases of hypertension; in a rigorously controlled trial in resistant hypertension (SYMPLICITY HTN-3), renal denervation did not reduce blood pressure over the long term. Is this because renal denerv …
In man, catheter ablation of renal nerves has been undertaken in the late phases of hypertension; in a rigorously controlled trial in resist …
Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study.
Lewin AJ, Kereiakes DJ, Chrysant SG, Izzo JL Jr, Oparil S, Lee J, Fernandez V, Melino M. Lewin AJ, et al. Among authors: izzo jl jr. Ethn Dis. 2014 Winter;24(1):41-7. Ethn Dis. 2014. PMID: 24620447 Clinical Trial.
The efficacy of triple-drug therapy in achieving BP goal was sustained long-term (40-week open-label extension period) in Hispanic/Latino (63.3%) and non-Hispanic/ Latino (64.2%) participants. ...
The efficacy of triple-drug therapy in achieving BP goal was sustained long-term (40-week open-label extension period) in Hispanic/La …
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.
Kereiakes DJ, Chrysant SG, Izzo JL Jr, Littlejohn T 3rd, Melino M, Lee J, Fernandez V, Heyrman R. Kereiakes DJ, et al. Among authors: izzo jl jr. Cardiovasc Diabetol. 2012 Oct 30;11:134. doi: 10.1186/1475-2840-11-134. Cardiovasc Diabetol. 2012. PMID: 23110471 Free PMC article. Clinical Trial.
CONCLUSIONS: In patients with diabetes, CKD, or chronic CVD, short-term (12 weeks) and long-term treatment with OM 40/AML 10/HCTZ 25 mg was well tolerated, lowered BP more effectively, and enabled more participants to reach BP goal than the corresponding 2-component …
CONCLUSIONS: In patients with diabetes, CKD, or chronic CVD, short-term (12 weeks) and long-term treatment with OM 40/AML 10/H …
Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.
Kereiakes DJ, Chrysant SG, Izzo JL Jr, Littlejohn T 3rd, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Kereiakes DJ, et al. Among authors: izzo jl jr. J Clin Hypertens (Greenwich). 2012 Mar;14(3):149-57. doi: 10.1111/j.1751-7176.2011.00588.x. Epub 2012 Jan 24. J Clin Hypertens (Greenwich). 2012. PMID: 22372774 Free PMC article. Clinical Trial.
At the end of the study, 44.5% to 79.8% of participants reached BP goal and the mean BP decreased from 168.6/100.7 mm Hg (baseline BP at randomization) to 125.0 to 136.8 mm Hg/77.8 to 82.5 mm Hg, depending on treatment. Long-term treatment with OM/AML/HCTZ was well tolerat …
At the end of the study, 44.5% to 79.8% of participants reached BP goal and the mean BP decreased from 168.6/100.7 mm Hg (baseline BP at ran …
Angiotensin-converting enzyme inhibitors.
Izzo JL Jr, Weir MR. Izzo JL Jr, et al. J Clin Hypertens (Greenwich). 2011 Sep;13(9):667-75. doi: 10.1111/j.1751-7176.2011.00508.x. Epub 2011 Jul 18. J Clin Hypertens (Greenwich). 2011. PMID: 21896148 Free PMC article. Review.
Increased serum creatinine (decreased glomerular filtration rate) during acute or chronic angiotensin-converting enzyme inhibition identifies individuals likely to experience long-term renal protective benefits. Angiotensin-converting enzyme inhibitors are contraindicated …
Increased serum creatinine (decreased glomerular filtration rate) during acute or chronic angiotensin-converting enzyme inhibition identifie …
Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results.
Zion AS, Izzo JL Jr. Zion AS, et al. Among authors: izzo jl jr. Expert Rev Cardiovasc Ther. 2011 Apr;9(4):421-7. doi: 10.1586/erc.11.23. Epub 2011 Mar 18. Expert Rev Cardiovasc Ther. 2011. PMID: 21417713 Review.
Aliskiren is the first of the direct renin inhibitors, the newest subclass of RAS blockers. In both short- and long-term studies, aliskiren has been shown to be similar in efficacy and tolerability compared with other RAS blockers, with the added benefit that its effects p …
Aliskiren is the first of the direct renin inhibitors, the newest subclass of RAS blockers. In both short- and long-term studies, ali …
Combination therapy in hypertension.
Gradman AH, Basile JN, Carter BL, Bakris GL; American Society of Hypertension Writing Group. Gradman AH, et al. J Clin Hypertens (Greenwich). 2011 Mar;13(3):146-54. doi: 10.1111/j.1751-7176.2010.00397.x. Epub 2010 Dec 10. J Clin Hypertens (Greenwich). 2011. PMID: 21366845 Free PMC article.
Although the choice of initial drug therapy exerts some effect on long-term outcomes, it is evident that BP reduction per se is the primary determinant of CV risk reduction. ...
Although the choice of initial drug therapy exerts some effect on long-term outcomes, it is evident that BP reduction per se is the p …
Combination therapy in hypertension.
Gradman AH, Basile JN, Carter BL, Bakris GL, Materson BJ, Black HR, Izzo JL Jr, Oparil S, Weber MA. Gradman AH, et al. Among authors: izzo jl jr. J Am Soc Hypertens. 2010 Mar-Apr;4(2):90-8. doi: 10.1016/j.jash.2010.03.001. J Am Soc Hypertens. 2010. PMID: 20400053
Although the choice of initial drug therapy exerts some effect on long-term outcomes, it is evident that BP reduction per se is the primary determinant of CV risk reduction. ...
Although the choice of initial drug therapy exerts some effect on long-term outcomes, it is evident that BP reduction per se is the p …
16 results